These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 3585412)
1. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. Watanabe Y; Iwa T J Biol Response Mod; 1987 Apr; 6(2):169-80. PubMed ID: 3585412 [TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy for lung cancer by streptococcal preparation OK-432]. Watanabe Y; Shimizu J; Yoshida Y; Hashizume Y; Yamada T; Iwa T Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1432-5. PubMed ID: 2586434 [TBL] [Abstract][Full Text] [Related]
3. [Surgery and adjuvant therapy of non-small cell lung cancer]. Watanabe Y; Yamada T; Ichihashi T; Hashizume Y; Iwa T Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1534-46. PubMed ID: 3524465 [TBL] [Abstract][Full Text] [Related]
4. [Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy]. Watanabe Y; Sato H; Iida S; Yamada T; Kobayashi H; Kimoto H; Tsunamura Y; Ichihashi T; Shimizu J; Hashizume Y Gan To Kagaku Ryoho; 1985 Jan; 12(1):21-35. PubMed ID: 2981515 [TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. Sakamoto J; Teramukai S; Watanabe Y; Hayata Y; Okayasu T; Nakazato H; Ohashi Y; J Immunother; 2001; 24(3):250-6. PubMed ID: 11394503 [TBL] [Abstract][Full Text] [Related]
6. [Immunochemotherapy of resectable lung cancer--a preliminary study on a comparison of the control, levamisole, and OK-432]. Okayasu T; Kashimura Y; Matano J; Kawabata M; Takeoka T; Hashimoto M; Tanabe T Gan To Kagaku Ryoho; 1982 Sep; 9(9):1646-52. PubMed ID: 6764120 [TBL] [Abstract][Full Text] [Related]
7. Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Watanabe Y; Iwa T Cancer; 1984 Jan; 53(2):248-53. PubMed ID: 6690008 [TBL] [Abstract][Full Text] [Related]
8. [A randomized controlled study of post-operative adjuvant therapy in non-small cell lung cancer]. Fukushima M; Tsushima T; Ito H; Fukuda Y; Maruyama A; Fujita H; Yagihashi N; Tsuge T; Ishioka T; Kudo T; Kishibe S; Sato T; Machida S; Kogawa R; Takashima K; Koie H; Fujita K Gan To Kagaku Ryoho; 1996 Feb; 23(3):303-9. PubMed ID: 8712823 [TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of immunotherapy for lung cancer--present and future]. Watanabe Y; Shimizu J; Oda M; Yoshida M; Watanabe S; Iwa T Nihon Geka Gakkai Zasshi; 1991 Sep; 92(9):1217-20. PubMed ID: 1944190 [TBL] [Abstract][Full Text] [Related]
10. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Kimura H; Yamaguchi Y Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707 [TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy of gastric cancer]. Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771 [TBL] [Abstract][Full Text] [Related]
12. [Transfer factor immunochemotherapy for primary lung cancer--evaluation of histologic types]. Fujisawa T; Yamaguchi Y Gan No Rinsho; 1983 Oct; 29(12):1409-16. PubMed ID: 6315989 [TBL] [Abstract][Full Text] [Related]
13. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer]. Kikkawa N; Sasai H; Kawahara T Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832 [TBL] [Abstract][Full Text] [Related]
14. [Relation between prognosis and the Su-PS skin reaction in patients with non-resected primary lung cancer receiving OK-432]. Nakarai I; Rikitake H; Koga T; Hayashi A; Harada Y; Takamoto M; Ishibashi T; Shinoda A; Sagawa K Gan To Kagaku Ryoho; 1987 Nov; 14(11):3050-7. PubMed ID: 2823723 [TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma]. Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399 [TBL] [Abstract][Full Text] [Related]
16. [Randomized controlled study of OK-432 in the treatment of cancerous pleurisy]. Urata A; Nishimura M; Ota K Gan To Kagaku Ryoho; 1983 Jun; 10(6):1497-503. PubMed ID: 6409006 [TBL] [Abstract][Full Text] [Related]
17. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Kimura T; Suzuki K; Motai H; Miyamoto N; Tsuge I; Ito Y; Baba S Acta Otolaryngol Suppl; 1996; 525():135-41. PubMed ID: 8908288 [TBL] [Abstract][Full Text] [Related]
18. Immuno-chemotherapy of malignant lymphoma using OK-432, a streptococcal agent. Kimura I; Ohnoshi T; Nakata Y; Takasugi K; Fujii M; Hayashi K; Kataoka M; Sato M; Nishihara R Acta Med Okayama; 1979 Dec; 33(6):471-8. PubMed ID: 94239 [TBL] [Abstract][Full Text] [Related]
19. [A controlled study of surgical adjuvant chemoimmunotherapy with FT-207 and OK-432 for advanced stomach cancer: the fourth study]. Yamamura Y; Yasue M; Nakazato H; Ota K Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):541-8. PubMed ID: 3923941 [TBL] [Abstract][Full Text] [Related]
20. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group. J Thorac Cardiovasc Surg; 1985 Jun; 89(6):842-7. PubMed ID: 2860271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]